By Catherine Novotny. Abortion is back on the Supreme Court’s docket—this time over the FDA’s prior approval of mifepristone, a medication abortion drug legally accessible to patients via mail. The drug represents one of the last remaining pathways to abortion for residents of states with strict restrictions. The impending decision may also threaten other aspects of reproductive care, such as access to birth control like the morning-after pill.
The Real Cost of Limiting Access to Abortion Services
Many states are enacting new legislation to shut down abortion clinics by adding draconian restrictions and requirements that are impossible for most clinics to meet. For example, Arizona and Texas passed bills outlawing FDA-approved abortion-inducing medication, forcing women seeking abortions to undergo more invasive and time-consuming surgical abortions instead. Arizona's attempt at enforcing a ban on … Continue reading The Real Cost of Limiting Access to Abortion Services
Law Journal for Social Justice 